Andere talen Invex Therapeutics Ltd

Aandelen

IXC

AU0000048621

Vertraagde tijd Australian S.E. Andere beurzen 04:26:51 08-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,078 ^AUD	-7,14%		-2,50%	-3,70%

16/02	Invex Therapeutics verkleint het verlies in het eerste halfjaar door lagere R&D-uitgaven	MT
15/02	Invex Therapeutics Ltd rapporteert resultaten voor het halfjaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	20/03
Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses	16/02
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	15/02
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	22/12
Invex Therapeutics to Secure European Patent Grant for Neurological Medication	22/11
Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director	08/11
Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	17-08-23
Invex Therapeutics Ltd Announces Board Changes	03-07-23
Invex Therapeutics Jumps 19% After Securing Second European Orphan Drug Designation for Exenatide	23-06-23
Invex Therapeutics Secures Approval for IIH EVOLVE Phase III Trial in France; Shares Rise 7%	21-04-23
Israel's Ministry of Health Approves Invex Therapeutics' IIH EVOLVE Clinical Trial	20-04-23
Invex Therapeutics Secures Clearance for Phase 2 Neurological Trial in Germany; Shares Rise 4%	20-03-23
Invex Therapeutics Ltd Announces the Approval to Commence the IIH EVOLVE Phase III Clinical Trial	19-03-23
Invex Therapeutics Ltd. Announces the Publication of the Invex Phase II 'Pressure' Clinical Trial	13-03-23
Invex Therapeutics More Than Doubles Fiscal H1 Loss	17-02-23
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	16-02-23
Invex Therapeutics Opens First US Clinical Trial Site in Texas	19-01-23
Invex Therapeutics Ltd Announces First US Clinical Site Activated in IIH Evolve Phase III Clinical Trial	18-01-23
Invex Therapeutics Gains European Regulator Approval for Pediatric Plan	14-12-22
Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA	13-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Invex Therapeutics Ltd

Aandelen

IXC

AU0000048621

Andere talen

Filters